English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Injection drug users (IDUs) account for more than 60% of all new hepatitis C virus (HCV) infections in the United States.1,2 Fifty to eighty percent of new IDUs are infected within 6 to 12 months of initial injection.3 Current treatment regimens are not highly effective, and no vaccine against HCV is available.1,4–7  Studies suggest that drug treatment and syringe exchange programs may play a role in reducing HCV infection among participants by promoting drug abstinence or safer injection practices among those who continue to use drugs.3,8–12 The New York City Department of Health conducted a survey of local drug treatment and syringe exchange programs to determine whether their HCV screening and counseling practices were carried out, as recommended in recent federal guidelines.1

Hepatitis C Screening and Management Practices: A Survey of Drug Treatment and Syringe Exchange Programs in New York City